This study tested whether levofloxacin, at a new high dose of 750 mg, was effective for the treatment of complicated skin and skin-structure infections (SSSIs). Patients with complicated SSSIs ( ) were randomly assigned n p 399 in a ratio of 1:1 to 2 treatment arms: levofloxacin (750 mg given once per day intravenously [iv], orally, or iv/ orally) or ticarcillin-clavulanate (TC; 3.1 g given iv every 4-6 hours) followed, at the investigator's discretion, by amoxicillin-clavulanate (AC; 875 mg given orally every 12 hours). In the clinically evaluable population, therapeutic equivalence was demonstrated between the levofloxacin and TC/AC regimens (success rates of 84.1% and 80.3%, respectively). In the microbiologically evaluable population, the overall rate of eradication was 83.7% in the levofloxacin treatment group and 71.4% in the TC/AC treatment group (95% confidence interval, Ϫ24.3 to Ϫ0.2). Both levofloxacin and TC/AC were well tolerated. These data demonstrate that levofloxacin (750 mg once per day) is safe and at least as effective as TC/AC for complicated SSSIs.
sponse, or underlying illnesses that impedes healing. These infections are often polymicrobial and result in hospitalization for parenteral therapy [1] .
Various antimicrobial regimens, including use of fluoroquinolones, have been compared in the treatment of complicated SSSIs and have been found to be effective and safe [2] [3] [4] [5] [6] [7] [8] [9] . Levofloxacin is an extended-spectrum fluoroquinolone with demonstrated activity against gram-positive and -negative aerobes, which have been implicated in complicated and uncomplicated SSSIs. A 500-mg daily dose was as effective clinically as ciprofloxacin (500 mg) for the treatment of uncomplicated SSSIs [10] [11] [12] [13] . Levofloxacin also exhibits in vitro activity against clinical isolates of anaerobes, including non-fragilis Bacteroides, Veillonella, and Prevotella species [14] . 
Infection in immunosuppressed subjects
Those with HIV infections and CD4 cell counts 1200 cells/mm 3 Those receiving long-term treatment with systemic steroids (120 mg of prednisone or the equivalent)
Those with diabetes mellitus necessitating treatment with hypoglycemic agents
Levofloxacin administered at a higher dose (750 mg) than customarily is used for pneumonia (500 mg) or urinary tract (250 mg) infections ensures that high concentrations of drug reach the site of infection, even in subjects with reduced vascularization. High tissue levels result in high ratios of area under the curve (AUC) to MIC and of peak concentration to MIC, which have been associated with favorable outcomes for fluoroquinolones [15, 16] , including levofloxacin [17] . Recent pharmacokinetic studies have demonstrated that levofloxacin penetrates effectively into the skin and skin structures of healthy individuals at 750-mg doses, reaching a mean (‫ע‬SD) peak concentration of mg per gram of skin tissue and 11.77 ‫ע‬ 0.81 a mean (‫ע‬SD) ratio of skin tissue to plasma of 1.97 ‫ע‬ 0.35 [18] . This level is 23.5 times the in vitro MIC of Staphylococcus aureus. In associated studies, the tolerability of levofloxacin (750 mg) was similar to that of levofloxacin (500 mg) [19, 20] . The present study tests the hypothesis that high doses of levofloxacin (750 mg) administered once daily (oral, iv, or iv/oral) are effective and safe for treating complicated SSSIs.
MATERIALS AND METHODS

Study population.
In this study, we enrolled male and female patients (age, у18 years) with a diagnosis of bacterial SSSI in the presence of a complicating factor, including preexisting skin lesions or underlying conditions that were adversely affecting the immunologic or tissue-healing response or the delivery of drug to the infected area (table 1) . At least 2 of the following clinical signs and symptoms of skin infection were required for inclusion in the study: pain, swelling, erythema, and induration. Subjects with multiple skin sites of infection were allowed in the study unless they had multiple infected ulcers at distant sites. However, the most severely affected site, defined by the lesion characteristics of tenderness, erythema, and swelling, was chosen for study.
Many of the infections had not been cured by prior oral therapy. Patients were randomized to 1 of the 2 study arms: ticarcillin-clavulanate (TC; 3.1 g given iv every 4-6 h) with a switch to oral amoxicillin-clavulanate (AC; 875 mg b.i.d.) at the investigator's discretion, or levofloxacin (750 mg given by mouth [po] and/or iv q.d.). The randomization schedule was stratified by study center and by diagnosis of diabetic ulcer. The first dose of TC/AC was given in the general ward or in the emergency department. If the clinical condition allowed, the patient could be transferred to a home iv service to continue parenteral therapy. For stable patients, the entire course of levofloxacin could be provided orally. Patients were deemed stable if, at the investigator's discretion, significant clinical improvement was achieved. All patients maintained a temperature log for the first 3 days and were seen by the study physician on the first and third days.
Exclusion criteria included (1) furuncles, simple abscesses, or other minor superficial infections not warranting systemic antimicrobial therapy; (2) cellulitis not associated with com- Effective concomitant therapy 2 7
Inappropriate bacteriologic culture 18 16 Lost to follow-up 6 16 Other protocol violation label, randomized study in the United States conducted from January 1997 through August 1998. Blinding was not feasible, given the complexity of the dosing regimens. All study protocols, informed-consent forms, and amendments were reviewed and approved by the center's institutional review boards. Patients in the levofloxacin group received 750 mg of medication once daily, in the morning, if possible. The iv dose (750 mg in 150 mL of 5% dextrose and water) was administered over 90 min. The oral tablets (one 250-mg tablet and one 500-mg tablet) were taken together. The duration of therapy was 7-14 days for both regimens, as clinically indicated. If, in the investigator's opinion, a patient required 114 days of therapy, the duration could be extended by contacting the medical monitor. Dose adjustments for renal impairment were made as follows: patients with a creatinine clearance of !30 mL/min were excluded from the study, and, for patients with a creatinine clearance of 30-49 mL/min, the dosing interval was increased from 24 h to 48 h.
Collection of clinical and microbiological data. Signs and symptoms of SSSIs were recorded at enrollment, during the course of antimicrobial administration (on-therapy visit), 2-5 days after completion of therapy (posttherapy visit), and 3-4 weeks after completion of therapy (poststudy visit). All patients with a successful outcome at the posttherapy visit were to return for evaluation of relapse at the poststudy visit.
For microbiological analysis, specimens of the lesion were obtained at admission to the study and were transported, processed, and interpreted according to standard policies and guidelines [21] . Specimens of infected ulcers were obtained only by needle aspiration or biopsy to avoid contamination with superficial colonizing bacterial flora that may not have represented the causative pathogen. If a clinically significant lesion or drainage persisted, a skin specimen was obtained at the posttherapy and poststudy visits.
Evaluation of clinical and microbiological efficacies. The investigator assessed clinical efficacy at the posttherapy visit and classified it as "cure," "improvement," "failure," or "unable to evaluate." For patients who left the study early for reasons other than clinical failure, an evaluation of "improvement" was given to indicate a patient's microbial resolution and the expectation of a successful outcome had the patient continued.
Microbiological efficacy was determined on the basis of the results of cultures of samples obtained at the posttherapy visit from the original infection site. Response categories included Table 4 . Study completion/withdrawal information for the intent-to-treat population in a comparative trial of levofloxacin versus ticarcillin-clavulanate (TC)/amoxicillin-clavulanate (AC) for the treatment of complicated skin and skin-structure infections. "eradication," "presumed eradication," "persistence," "presumed persistence," "persistence with acquisition of resistance," and "unknown." "Presumed persistence" was defined as clinical failure in patients from whom samples for test-of-cure culture were not taken or for whom no pathogen was isolated after completion of study therapy or other potentially effective systemic antimicrobial therapy. "Persistence with acquisition of resistance" was defined as a recovered pathogen that acquired resistance to the agent used for the treatment. "Unknown" was used for patients who were either lost to follow-up or had negative culture results attained in the presence of antimicrobials administered for a condition other than the original SSSI. These antimicrobials could have been effective against the skin pathogen isolated at admission to the study.
Evaluation of safety. All patients were evaluated for the emergence of adverse events during treatment that were new in onset or aggravated in severity or frequency after administration of a study drug. Adverse events were considered to be drug related if their relationship to the drug was considered definite or probable.
Statistical methods. The primary efficacy variable was the posttherapy clinical response. A minimum of 5 days of therapy was required for inclusion; however, subjects who took a study drug for 12 days (148 h) and !5 days (!120 h) but who discontinued treatment because of clinical failure were considered evaluable. Patients were considered microbiologically evaluable if they were clinically evaluable, if they had a pathogen isolated at admission to the study, and if subsequent microbiological assessments were performed at the appropriate times. In the statistical analysis, the responses of "cure" and "improvement" were combined into 1 category of "clinical success," and the responses of "failure" and "unable to evaluate" were combined into 1 category of "failure." A 2-sided 95% CI around the difference in clinical success rates between the levofloxacin arm and the TC/AC arm was the basis for assessing therapeutic equivalence and for computing the clinical success per pathogen, microbiological eradication comparability rate, and poststudy clinical response; comparability between treatment groups was similarly computed.
RESULTS
Study population.
Four hundred patients were enrolled in the study. In error, 1 patient's readmission resulted in rerandomization, producing a protocol violation. The data for this patient were not included in the efficacy evaluations; however, the safety data were used. The demographic and baseline characteristics are shown in table 5 ). The clinical response rates for patients stratified by sex and race were generally consistent with the results observed for the clinically evaluable population as a whole. Levofloxacin administered once daily at the higher dose was as effective as TC/AC for treatment of complicated SSSIs at the posttherapy visit. Fortyfour patients in the clinically evaluable population received oral levofloxacin exclusively from the time of admission to the study; of these patients, 40 (90.9%) were determined to have had clinical success.
This study was also stratified at enrollment according to diagnosis of diabetic ulcer. Of the 399 patients in the intentto-treat arm of the study, 67 had diabetic ulcer infections (36 received levofloxacin and 31 received TC/AC). In both groups, the clinical success rate appeared to be lower in the infected diabetic ulcer stratum (69.2% for levofloxacin and 57.1% for . The microbiological eradication rates observed for the 2 groups were generally consistent. In the microbiologically evaluable population, 35 patients received oral levofloxacin exclusively from the time of admission to the study; 33 (94.3%) were clinical successes.
The eradication rates at the posttherapy visit for individual pathogen categories are in table 7. Gram-positive aerobes made up 63.9% of the total pathogens in the levofloxacin group and 66.9% in the TC/AC group. Other pathogens included gramnegative aerobes (26.0% in the levofloxacin group and 29.8% in the TC/AC group) and anaerobes (10.1% and 3.3%, respectively). The microbiological eradication rates for gram-positive aerobes were 86.1% for levofloxacin and 74.3% for TC/ AC (95% CI, Ϫ23.1 to Ϫ0.6). For gram-negative aerobes, the microbiological eradication rates for levofloxacin and TC/AC were 84.1% and 68.9%, respectively (95% CI, Ϫ33.7 to 3.2). The microbiological eradication rates for obligate anaerobic pathogens were 100% for both levofloxacin (17 of 17) and TC/ AC (5 of 5). Infections due to isolates of Pseudomonas aeruginosa that were susceptible to levofloxacin were all treated successfully, whereas those due to isolates with MICs of 12 mg/ mL were not, which suggests that this organism also responds to levofloxacin therapy, providing the organism demonstrates in vitro susceptibility.
All pathogens isolated at admission to the study from the intent-to-treat population were analyzed for in vitro susceptibility to study drugs (table 8) . Overall, 486 pathogens were isolated (256 from the levofloxacin group and 230 from the TC/AC group). Of the 435 tested against levofloxacin, 397 (91.3%) were susceptible, 6 (1.4%) were intermediate, and 32 (7.4%) were resistant. For TC/AC, 368 (84.4%) of 436 tested were susceptible, 1 (0.2%) was intermediate, and 67 (15.4%) were resistant. For AC, 357 (81.9%) of 436 were susceptible, 7 (1.6%) were intermediate, and 72 (16.5%) were resistant.
Safety. All 400 patients were included in the safety evaluation (table 9). The incidence of adverse events, regardless of relationship to study drug, was similar for the 2 treatment arms (95% CI, Ϫ2.0 to 18.0). The gastrointestinal system was the site of most adverse events reported in both groups, the most common complaints being nausea and constipation. Seven patients taking levofloxacin and 2 taking TC/AC had osteomyelitis diagnosed after admission to the study, resulting in 4 amputations. Five of 9 of the osteomyelitis cases were primarily due to diabetic ulcers; the other 4 included chronic osteomyelitis on a finger, 2 wound infections in toes, and a nondiabetic plantar ulcer with cellulitis on the foot. None of these 9 cases were associated with treatment failure but, rather, were preexisting infections that were radiographically undetectable at the time of enrollment. The investigators judged the bone infections to be unrelated to study medications.
The majority of adverse events were mild or moderate; 20 (10.0%) of 201 of the patients taking levofloxacin and 14 Table 7 . Microbiological eradication rates at the 2-5-day posttherapy visit in patients who were evaluable for microbiological efficacy in a comparative trial of levofloxacin versus ticarcillin-clavulanate (TC)/amoxicillin-clavulanate (AC) for the treatment of complicated skin and skin-structure infections. TC/AC eradicated pathogens from 1 species of non-fragilis Bacteroides and 1 species of Veillonella. f Eradication of all pathogens isolated from a patient at admission.
(7.0%) of 199 of the patients taking TC/AC had adverse events of marked severity. Two patients taking levofloxacin had dysuria and diarrhea, and 2 patients taking TC/AC had serum sickness and genital pruritus. The events were of marked severity and defined as probably related to the drug. All other adverse events of marked severity were unrelated, remotely related, or possibly related to study medication. Possible related adverse events included 1 case each of leg cramps, dizziness, dyspnea, and confusion. All adverse events in this trial were consistent with the known safety profiles of the study drugs. Therefore, both regimens were well tolerated in this study.
DISCUSSION
The present study validated the hypothesis that levofloxacin (750 mg given po, iv, or iv/po q.d.), is effective for the treatment of complicated SSSIs. Clinical response rates for both regimens were equivalent, with significantly higher microbiological eradication rates in the levofloxacin group. Both treatments had similar rates of relapse and new infection. The 750-mg dose appeared to be as well tolerated as the 500-mg doses studied elsewhere [22] . Several antimicrobial regimens are effective for treatment of complicated SSSIs [2] [3] [4] [5] 23] . The primary advantages of levofloxacin may be its simple once-daily dosing and optional oral administration that may provide speedy iv-to-oral conversion, thereby decreasing the duration of the average hospital stay [2] [3] [4] [5] [6] [7] [8] [9] . It is significant that 44 patients in the clinically evaluable population received oral levofloxacin exclusively from the time of admission to the study. Clinical outcomes in these patients were good (success rate, 90.9%); however, the stability of the patients who were taking oral therapy from the start could have influenced the outcome. Another advantage may be that levofloxacin, like other fluoroquinolones, is rapidly bactericidal, an important consideration for treatment of these difficult-to-treat infections. Any antimicrobial that is effective against complicated SSSIs must act against an array of bacteria. The eradication rate for the trial's most common aerobe, methicillin-susceptible S. aureus, was statistically higher for levofloxacin than for TC/AC. Although published reports have indicated that clinical isolates of methicillin-resistant S. aureus are often resistant to fluoroquinolones [23] , the outcome for this pathogen in this study was favorable (4 of 5 isolates were eradicated by levofloxacin). However, caution should be heeded regarding the potential emergence of resistance to fluoroquinolones among methicillin-resistant S. aureus isolates.
The success of levofloxacin was consistent with a pharmacodynamic study published elsewhere of 313 patients treated with levofloxacin once daily for respiratory tract (dose, 500 mg), skin (dose, 500 mg), and urinary tract (dose, 250 mg) infections [17] . For 134 of these patients, pathogens were isolated from the primary sites of infection, and their MIC values were determined. In the same patients, plasma concentrations of levofloxacin were determined at 6 time points after administration, from which mean AUC and maximum concentration (C MAX ) values were calculated by statistical modeling. Therapeutic outcome correlated most closely with the ratio of C MAX to AUC. Clinical success rates were 99.0% for patients who achieved a ratio of C MAX to MIC of у12.2.
In a recent study, penetration of 750-mg doses of levofloxacin into skin tissue of healthy volunteers was determined by analyzing skin-punch biopsy samples [18] . These studies estimated a mean (‫ע‬SD) C MAX value for levofloxacin of mg per gram 11.77 ‫ע‬ 0.81 of skin tissue. This value can be used to estimate the ratio of C MAX to MIC for the pathogens identified in the present study. For example, the published MIC 90 of levofloxacin for S. aureus, the most common pathogen identified in this study, is 0.5 mg/ mL [22] . When this value is used, the estimated ratio of C MAX to MIC, under the assumption that the patient was healthy, would be 23.5, which is nearly twice the level shown to correlate with a 99% clinical success rate. Favorable ratios were reached for a majority of the infecting pathogens in the present study.
In summary, levofloxacin (750 mg given po and/or iv q.d.) was safe and effective for the treatment of complicated SSSIs. It produced clinical success results similar to an iv regimen of TC with multiple doses per day, with or without followup oral therapy with AC. Levofloxacin had a higher microbiological eradication rate and was superior in eradicating some subcategories of pathogens, including the most common pathogen, methicillin-susceptible S. aureus. Both regimens were well tolerated, with drug-related adverse event profiles consistent with published safety profiles for these antimicrobials. Once-daily dosing with 750 mg of levofloxacin may offer therapeutic advantages for the treatment of complicated SSSIs.
